Cargando…
Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer
Basal-like breast cancer is an incurable disease with limited therapeutic options, mainly due to the frequent development of anti-cancer drug resistance. Therefore, identification of druggable targets to improve current therapies and overcome these resistances is a major goal. Targeting DNA repair m...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730833/ https://www.ncbi.nlm.nih.gov/pubmed/33261142 http://dx.doi.org/10.3390/ijms21239034 |
_version_ | 1783621775250161664 |
---|---|
author | Nieto-Jimenez, Cristina Alcaraz-Sanabria, Ana Martinez-Canales, Sandra Corrales-Sanchez, Veronica Montero, Juan Carlos Burgos, Miguel Nuncia-Cantarero, Miriam Pandiella, Atanasio Galan-Moya, Eva M. Ocaña, Alberto |
author_facet | Nieto-Jimenez, Cristina Alcaraz-Sanabria, Ana Martinez-Canales, Sandra Corrales-Sanchez, Veronica Montero, Juan Carlos Burgos, Miguel Nuncia-Cantarero, Miriam Pandiella, Atanasio Galan-Moya, Eva M. Ocaña, Alberto |
author_sort | Nieto-Jimenez, Cristina |
collection | PubMed |
description | Basal-like breast cancer is an incurable disease with limited therapeutic options, mainly due to the frequent development of anti-cancer drug resistance. Therefore, identification of druggable targets to improve current therapies and overcome these resistances is a major goal. Targeting DNA repair mechanisms has reached the clinical setting and several strategies, like the inhibition of the CHK1 kinase, are currently in clinical development. Here, using a panel of basal-like cancer cell lines, we explored the synergistic interactions of CHK1 inhibitors (rabusertib and SAR020106) with approved therapies in breast cancer and evaluated their potential to overcome resistance. We identified a synergistic action of these inhibitors with agents that produce DNA damage, like platinum compounds, gemcitabine, and the PARP inhibitor olaparib. Our results demonstrated that the combination of rabusertib with these chemotherapies also has a synergistic impact on tumor initiation, invasion capabilities, and apoptosis in vitro. We also revealed a biochemical effect on DNA damage and caspase-dependent apoptosis pathways through the phosphorylation of H2AX, the degradation of full-length PARP, and the increase of caspases 3 and 8 activity. This agent also demonstrated synergistic activity in a platinum-resistant cell line, inducing an increase in cell death in response to cisplatin only when combined with rabusertib, while no toxic effect was found on non-tumorigenic breast tissue-derived cell lines. Lastly, the combination of CHK1 inhibitor with cisplatin and gemcitabine resulted in more activity than single or double combinations, leading to a higher apoptotic effect. In conclusion, in our study we identify therapeutic options for the clinical development of CHK1 inhibitors, and confirm that the inhibition of this kinase can overcome acquired resistance to cisplatin. |
format | Online Article Text |
id | pubmed-7730833 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77308332020-12-12 Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer Nieto-Jimenez, Cristina Alcaraz-Sanabria, Ana Martinez-Canales, Sandra Corrales-Sanchez, Veronica Montero, Juan Carlos Burgos, Miguel Nuncia-Cantarero, Miriam Pandiella, Atanasio Galan-Moya, Eva M. Ocaña, Alberto Int J Mol Sci Article Basal-like breast cancer is an incurable disease with limited therapeutic options, mainly due to the frequent development of anti-cancer drug resistance. Therefore, identification of druggable targets to improve current therapies and overcome these resistances is a major goal. Targeting DNA repair mechanisms has reached the clinical setting and several strategies, like the inhibition of the CHK1 kinase, are currently in clinical development. Here, using a panel of basal-like cancer cell lines, we explored the synergistic interactions of CHK1 inhibitors (rabusertib and SAR020106) with approved therapies in breast cancer and evaluated their potential to overcome resistance. We identified a synergistic action of these inhibitors with agents that produce DNA damage, like platinum compounds, gemcitabine, and the PARP inhibitor olaparib. Our results demonstrated that the combination of rabusertib with these chemotherapies also has a synergistic impact on tumor initiation, invasion capabilities, and apoptosis in vitro. We also revealed a biochemical effect on DNA damage and caspase-dependent apoptosis pathways through the phosphorylation of H2AX, the degradation of full-length PARP, and the increase of caspases 3 and 8 activity. This agent also demonstrated synergistic activity in a platinum-resistant cell line, inducing an increase in cell death in response to cisplatin only when combined with rabusertib, while no toxic effect was found on non-tumorigenic breast tissue-derived cell lines. Lastly, the combination of CHK1 inhibitor with cisplatin and gemcitabine resulted in more activity than single or double combinations, leading to a higher apoptotic effect. In conclusion, in our study we identify therapeutic options for the clinical development of CHK1 inhibitors, and confirm that the inhibition of this kinase can overcome acquired resistance to cisplatin. MDPI 2020-11-27 /pmc/articles/PMC7730833/ /pubmed/33261142 http://dx.doi.org/10.3390/ijms21239034 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nieto-Jimenez, Cristina Alcaraz-Sanabria, Ana Martinez-Canales, Sandra Corrales-Sanchez, Veronica Montero, Juan Carlos Burgos, Miguel Nuncia-Cantarero, Miriam Pandiella, Atanasio Galan-Moya, Eva M. Ocaña, Alberto Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer |
title | Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer |
title_full | Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer |
title_fullStr | Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer |
title_full_unstemmed | Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer |
title_short | Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer |
title_sort | checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730833/ https://www.ncbi.nlm.nih.gov/pubmed/33261142 http://dx.doi.org/10.3390/ijms21239034 |
work_keys_str_mv | AT nietojimenezcristina checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer AT alcarazsanabriaana checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer AT martinezcanalessandra checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer AT corralessanchezveronica checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer AT monterojuancarlos checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer AT burgosmiguel checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer AT nunciacantareromiriam checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer AT pandiellaatanasio checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer AT galanmoyaevam checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer AT ocanaalberto checkpointkinase1pharmacologicalinhibitionsynergizeswithdnadamagingagentsandovercomesplatinumresistanceinbasallikebreastcancer |